{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016403","form_type":"8-K","ticker":"CDT","cik":"0001896212","company_name":"CDT Equity Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.536074+00:00","generated_at":"2026-06-15T04:59:43.022474+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Murphy Canyon Acquisition Corp. amends merger agreement with Conduit Pharmaceuticals, extends outside date to Feb 2024","bullets":["Second amendment to merger agreement with Conduit Pharmaceuticals signed May 11, 2023.","Removes provision that no tax opinion would be delivered at closing.","Adds closing condition: Murphy must have at least $5,000,001 net tangible assets or be exempt from Rule 419.","Extends outside date for closing from May 31, 2023 to February 7, 2024.","Amendment executed by Murphy, Merger Sub, and Conduit."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016403","json":"https://secwatch.observer/filing/0001493152-23-016403.json","markdown":"https://secwatch.observer/filing/0001493152-23-016403.md","text":"https://secwatch.observer/filing/0001493152-23-016403.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223016403/0001493152-23-016403-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223016403/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:59:43.022474+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d0f46877ee83b2e1f8994b67f35edd4cd2e699f4","claim":"CDT Equity Inc. amended Second Amendment to the Merger Agreement with Conduit Pharmaceuticals Limited valued at Amendment to Merger Agreement to extend outside date and modify closing conditions. (effective 2023-05-11).","evidence_excerpt":"On May 11, 2023, the Company, Conduit, and Merger Sub entered into a Second Amendment to the Merger Agreement (the “Second Merger Amendment” and, together with the Original Merger Agreement and the First Merger Amendment, the “Merger Agreement”) to provide for (i) removal of the provision that indicates that no tax opinion would be delivered in connection with the closing of the Conduit Business Combination, (ii) a closing obligation that that the Company either (a) be exempt from the provisions of Rule 419 promulgated under the Securities Act of 1933, as amended, other than through its net tangible assets or (b) have at least $5,000,001 of net tangible assets either immediately prior to or upon consummation of the Conduit Business Combination, and (iii) the extension of the outside date for the closing of the Conduit Business Combination from May 31, 2023, to February 7, 2024.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315223016403/0001493152-23-016403-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Conduit Pharmaceuticals Limited"},{"label":"Value","value":"Amendment to Merger Agreement to extend outside date and modify closing conditions."},{"label":"Effective","value":"2023-05-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}